OCS Stock Analysis: Buy, Sell, or Hold?
OCS - Oculis Holding AG Ordinary shares
$13.09
-0.05 (-0.42%)
▼
5d:
+1.12%
30d:
+14.38%
90d:
-57.79%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 20, 2026
0d
Get Alerted When OCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: OCS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: OCS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: OCS is currently trading at $13.09, which is considered extended relative to its 30-day fair value range of $11.43 to $13.02.
Technical Outlook: Technically, OCS is in a strong downtrend. Immediate support is located at $12.31, while resistance sits at $13.70.
Market Sentiment: OCS scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.56 (+179.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OCS is in a strong downtrend. Immediate support is located at $12.31, while resistance sits at $13.70.
Market Sentiment: OCS scores 34/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $36.56 (+179.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$11.43 -
$13.02
Company Quality Score
39/100
(SELL)
Options IV Signal
46th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
35.4%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 46th percentile)
- BEARISH: Weak technical setup (34/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 179.4% below Wall St target ($36.56)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.43 -
$13.02
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.50
(11.4%)
Support & Resistance Levels
Support Level
$12.31
Resistance Level
$13.70
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.95
Wall Street Target
$36.56
(+179.4%)
Revenue Growth (YoY)
18.8%
Share & Embed Analysis
Last updated: August 23, 2026 6:30 PM ET
Data refreshes hourly during market hours. Next update: 7:30 PM
Data refreshes hourly during market hours. Next update: 7:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
